ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Payloads & linkers
Payload · Auristatin

MMAE

Tubulin inhibitor

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC
Physicochemistry

Properties

MW
718 Da
XLogP3
4.1
logD₇.₄
2.7
TPSA
150 Ų
pKa
9.1
Charge pH 7.4
+1
H-bond donors
4
H-bond acceptors
8
Bystander
Yes
PubChem CID
11542188
Bioactivity
ADCdb reports MMAE payload potency with IC50 as low as 1.9 pM in CD30+ Karpas-299 cells (range across cell lines up to ~3300 ng/mL). Mechanism: MMAE binds tubulin and disrupts microtubules, causing G2/M arrest and apoptosis after antigen-mediated internalization and Val-Cit linke
28 agents

ADCs built on this payload

Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
DP-303cERBB2
94.7
31.9
14.9
26.6
4.3
46.8
CRB-701 (SYS6002)NECTIN4
66
27
18.9
21
18.9
8.4
Tisotumab vedotinF3
55
34
16
41
33
2
38
Iladatuzumab vedotinCD79B
47
8
27
20
5
20
MYTX-011MET
47
33
0
0
5
36
36
Enfortumab vedotinNECTIN4
40
75
27
28
35
3
53
Sirtratumab vedotinSLITRK6
29
37.6
19.4
MRG-004AF3
27
17
Telisotuzumab vedotinMET
25
41
10
14
35
15
10
51
Samrotamab vedotin (ABBV-085)LRRC15
24.4
19
31
SYSA-1801CLDN18
21.2
Lifastuzumab vedotinSLC34A2
20
22
73
61
32
49
34
61
JK-06TPBG
10
10
DLYE5953A (RG-7841)LY6E
10
16
13
12
38
35
Pinatuzumab vedotinCD22
9.5
59
BRY-812SLC39A6
5.9
Brentuximab vedotinTNFRSF8
5
31
54
28
33
42
25
52
Disitamab vedotinERBB2
5
42.1
42.1
24.3
21.5
29
68.2
Polatuzumab vedotinCD79B
1.2
26
60
32
68
42
1.7
53
DMOT4039AMSLN
0
12
17
37
19
Zilovertamab vedotinROR1
0
23
31.4
13
27.5
48
Glembatumumab vedotinGPNMB
0
11.7
39.4
16.9
44.1
36.2
Indusatumab vedotinGUCY2C
0
28.6
25
17.9
39.3
52.6
0
10.5
OBI-999-
0
33.3
0
TORL-1-23CLDN6
0
11.9
31
25
29
0
25
FOR-46CD46
0
21
70
30
39
45
ATG-022CLDN18
0
10.8
37.8
37.8
EBC-129CEACAM5; CEACAM6
0
17
31
22
17
39
6
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed